HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences, Lupin sign licensing agreement to co-market Semaglutide Injection in India
Mar-17-2026

Zydus Lifesciences has entered into a Licensing and Supply Agreement with global pharma major, Lupin to expand access to innovative Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India. This partnership brings together the company’s strong product development capabilities and Lupin’s extensive reach in the Indian market, with the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market the company’s innovative Semaglutide Injection in the Indian market under the brand names Semanext and Lupin’s Livarise. The company will market the product under the brand names SEMAGLYN, MASHEMA and ALTERME. Lupin will pay the company upfront licensing fees and milestone payments on achieving pre-defined milestones.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


  RELATED NEWS >>